Provectus Algae programs microalgae to produce specialty ingredients using both natural and synthetic biology approaches. The strategic investment by CJ BIO provides Provectus Algae with additional funds to accelerate commercialization efforts.
Provectus Algae also expects to benefit from the experience and expertise CJ BIO has gained commercializing polyhydroxyalkanoates, lysine, tryptophan, nucleic acid, valine, and soy protein concentrate.
“[CJ BIO’s] experience providing sustainable solutions in specialty nutrition and health will be a tremendous asset going forward,” said Nusqe Spanton, Founder and CEO of Provectus Algae. “Our Precision Photosynthesis™ technology and sustainable biomanufacturing platform are an ideal complement to the many fermentation-based technologies CJ BIO has developed and deployed for the production of animal, human, and plant nutrition products as well as biomaterials and enzymes.”